Q1 26 EPS
$-0.71
BEAT +16.07%
Est. $-0.85
Q1 26 Revenue
$34.4M
BEAT +317.57%
Est. $8.2M
vs S&P Since Q1 26
+43.7%
BEATING MARKET
KYMR +48.3% vs S&P +4.6%
Market Reaction
Did KYMR Beat Earnings? Q1 2026 Results
Kymera Therapeutics delivered a standout first quarter for fiscal 2026, posting revenue of $34.37 million, a 55.5% increase year-over-year that ran well ahead of the $8.23 million consensus estimate, while its loss per share of $0.71 came in meaningf… Read more Kymera Therapeutics delivered a standout first quarter for fiscal 2026, posting revenue of $34.37 million, a 55.5% increase year-over-year that ran well ahead of the $8.23 million consensus estimate, while its loss per share of $0.71 came in meaningfully better than the $0.85 analysts had expected. The revenue outperformance was driven almost entirely by the company's collaboration with Gilead Sciences, which has become the anchor of Kymera's commercial relationships after replacing Sanofi as the primary revenue contributor. Gilead's decision to exercise its option to exclusively license KT-200, a CDK2 molecular glue degrader, triggering a $45 million milestone payment due in Q2 2026, underscored the strategic credibility behind the partnership model. New preclinical data for KT-579 showing biologics-like activity in inflammatory bowel disease models added further momentum to the quarter's narrative. With $1.55 billion in cash providing runway into 2029, Kymera looks toward pivotal readouts from its STAT6 degrader KT-621 in atopic dermatitis and asthma through 2027.
Key Takeaways
- • Gilead Sciences collaboration revenue drove Q1 2026 collaboration revenues of $34.4 million
- • Increased R&D investment in STAT6 program, platform and discovery programs
- • Interest and other income of $15.0 million contributed to offsetting operating losses
KYMR Forward Guidance & Outlook
Kymera expects its $1.55 billion cash position to provide runway into 2029 beyond multiple clinical inflection points. Key upcoming milestones include: BROADEN2 (AD) enrollment completion in 2026 with data by mid-2027; BREADTH (asthma) data in late 2027; KT-579 Phase 1 healthy volunteer data in 2H 2026; KT-485/SAR447971 clinical entry expected in 2026; and advancement of at least one new development candidate towards IND for a first-in-class oral program in 2026. The $45 million Gilead milestone payment for KT-200 is expected in Q2 2026.
KYMR YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
KYMR Revenue by Segment
With YoY comparisons, source: SEC Filings
“As we continue to advance KT-621 and KT-579 through clinical development, our focus remains on disciplined execution and delivering on multiple important milestones this year. We remain committed to translating our first-in-class science into better outcomes for patients. Our STAT6 and IRF5 oral degrader programs exemplify this mission, and the growing recognition of our work within the scientific and medical community further validates the potential of our approach. We are continuing to build on this foundation with the advancement of KT-200, our oral CDK2 molecular glue degrader partnered with Gilead, and through progress within our early-stage pipeline.”
— Nello Mainolfi, Q1 2026 Earnings Press Release
KYMR Earnings Trends
KYMR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
KYMR EPS Trend
Earnings per share: estimate vs actual
KYMR Revenue Trend
Quarterly revenue: estimate vs actual
KYMR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.85 | $-0.71 | +16.07% | $34.4M | +317.57% |
| Q4 25 MISS FY | $-0.79 | $-0.97 | -23.10% | $2.9M | -80.61% |
| FY Full Year | $-3.47 | $-3.69 | -6.46% | $39.2M | -26.90% |
| Q3 25 MISS | $-0.79 | $-0.94 | -19.50% | $2.8M | -88.06% |
| Q2 25 MISS | $-0.80 | $-0.95 | -19.12% | $11.5M | -52.51% |
| Q1 25 BEAT | $-0.91 | $-0.82 | +9.90% | $22.1M | +105.88% |